Among the B-CLL population analyzed, all characterized for having unmutated BTK and PLCγ2, six patients underwent to Ibrutinib therapy and three of them carried TP53 functional mutations, in different genetic sites and at different clonal frequency (Table 1 and Figure 1). Here, BTK is linked to B-cell chronic lymphocytic leukemia.